Cannabis Testing’s Next Phase: Standardization, Automation and Stronger Quality Controls
The cannabis testing market is likely to evolve as legal sales expand, but its future will depend less on federal legalization alone than on the development of reliable, comparable laboratory standards.
Testing laboratories already play a central role in regulated cannabis markets. Depending on the jurisdiction, labs may analyze products for cannabinoid and terpene content, pesticides, residual solvents, heavy metals, microbial contaminants, mycotoxins, moisture and foreign material. In California, for example, the Department of Cannabis Control requires every commercial batch to be tested before sale and requires laboratories to maintain quality systems, standard operating procedures, ISO accreditation and proficiency-testing participation.
The industry’s regulatory framework, however, remains fragmented. States have adopted different testing panels, sampling rules, reporting requirements and acceptable limits. That variation can make results difficult to compare across jurisdictions and creates additional compliance work for companies operating in multiple markets.
The MORE Act, or H.R. 3617, passed the House of Representatives on April 1, 2022, but it did not become law. The proposal would have removed marijuana from the federal Controlled Substances Act, created a federal excise-tax structure and established measures related to expungement and reinvestment. Its failure to pass illustrates why federal legalization should be treated as a possible long-term scenario rather than an imminent certainty.
If federal policy eventually permits broader interstate commerce, cannabis testing could become more geographically concentrated. Laboratories might serve customers across larger regions, reducing the need for a full-service facility in every state or local market. That outcome would depend on the details of any federal and state rules, including requirements for licensed sampling, chain of custody, transportation, product traceability and the preservation of sample integrity. Interstate commerce would not automatically make ordinary parcel shipment an acceptable substitute for regulated cannabis logistics.
Consolidation and accreditation
A more integrated market could also encourage consolidation among testing providers. Larger laboratories may be able to spread the cost of sophisticated instruments, specialized personnel, accreditation and quality-management systems across a broader customer base. Smaller laboratories could remain competitive by focusing on regional service, specialized analyses, faster turnaround times or research and development support.
Regardless of ownership structure, credibility will be essential. Accreditation to ISO/IEC 17025 provides an independent framework for assessing laboratory competence, while proficiency testing helps reveal whether different laboratories can produce comparable results. The National Institute of Standards and Technology has also developed cannabis reference materials, analytical methods and its Cannabis Laboratory Quality Assurance Program to improve measurement consistency.
These systems matter because cannabis testing is vulnerable to both technical and commercial pressures. Potency results can affect a product’s market value, while a failed contaminant test can force a batch to be remediated or destroyed. Strong sampling procedures, documented methods, instrument calibration, analyst training, quality-control samples and transparent reporting are therefore as important as the analytical instruments themselves.
Automation and data management
Higher sample volumes will increase the appeal of automation. Robotic systems can standardize repetitive steps such as weighing, extraction, dilution, centrifugation and filtration, reducing manual variation and freeing analysts to focus on review and interpretation. An Agilent application study on automated terpene sample preparation, for example, describes a workflow designed to reduce bench errors and support higher-throughput analysis. Such demonstrations show technical potential, but they do not by themselves establish that automation will improve every laboratory’s accuracy or economics.
Laboratory information management systems, or LIMS, will also become increasingly important. A well-designed system can track samples from receipt through analysis and reporting, connect instruments with analytical records, manage chain-of-custody documentation, preserve audit trails and generate certificates of analysis. As laboratories handle more samples and more complex test panels, secure data storage and controlled review processes will be central to maintaining confidence in results.
Beyond mandatory compliance testing
Compliance testing is only one potential source of laboratory revenue. Labs can also support cultivators and manufacturers with in-process testing, screening of soil, water and other inputs, environmental monitoring, stability studies, method development and investigations into pests, pathogens or production problems.
These services can give laboratories a role in improving processes before a finished product reaches the compliance stage. They may also help businesses identify contamination or formulation problems earlier, when corrective action is less expensive.
The outlook for cannabis testing is therefore promising, but not guaranteed. Growth in legal production should create demand for analytical services, while standardization, accreditation, automation and data integrity will determine which laboratories earn lasting trust. Federal legalization could accelerate those trends, but the sector’s most important development may be the steady construction of testing systems that produce accurate, reproducible and meaningful results across markets.
